bims-mithem Biomed News
on Mitochondria in Hematopoiesis
Issue of 2026–11–01
five papers selected by
Tim van Tienhoven, Erasmus Medical Center



  1. bioRxiv. 2026 Sep 02. pii: 2026.09.01.747091. [Epub ahead of print]
      Aged hematopoietic stem cells (HSCs) exhibit a shift from balanced to myeloid-biased differentiation, resulting in reduced lymphoid output and impaired adaptive immunity. The question of whether this lineage bias is established in a subset of HSCs during early development or primarily emerges with aging warrants further investigation. Here, we investigate whether myeloid-biased HSCs (my-HSCs) are established at the fetal liver stage by specifically examining Neogenin-1 (NEO1), a previously defined marker of my-HSCs. We identify two distinct populations of Hoxb5 + HSCs in the fetal liver: NEO1 + and NEO1, with NEO1 + HSCs exhibiting transcriptional and functional characteristics consistent with my- HSCs. With age, my-HSC-associated transcriptional programs become increasingly reinforced across the Hoxb5 + pHSC compartment, with NEO1 + cells showing early enrichment of this program and both NEO1 + and NEO1 - cells acquiring broader myeloid-biased features in aging. These findings suggest that lineage programming can begin early in development and is further shaped by age-related changes, potentially contributing to the functional decline observed in the aging hematopoietic system.
    DOI:  https://doi.org/10.64898/2026.09.01.747091
  2. Rinsho Ketsueki. 2026 ;67(9): 1061-1068
      Myeloid neoplasia comprises a spectrum of disorders now recognized as a continuum, ranging from clonal hematopoiesis to overt disease. Recent genomic studies have shown that hematopoietic stem cells (HSCs) harboring somatic mutations undergo clonal expansion long before clinical manifestation. Although these mutant stem cells often retain multilineage differentiation potential, their intrinsic functions-including self-renewal capacity and differentiation dynamics-are altered. In addition, accumulating evidence indicates that differentiated progeny derived from mutant stem cells exhibit functional abnormalities, such as dysregulated inflammatory responses and altered interactions with the bone marrow microenvironment. These alterations, spanning both stem cell and differentiated cell compartments, contribute to inflammatory conditions, remodeling of the bone marrow niche, and the establishment of a selective environment that promotes clonal expansion while impairing normal hematopoiesis. In this educational review, I summarize recent advances in understanding dysregulated HSC control in the early stages of myeloid neoplasia, with particular emphasis on aging, inflammation, immune interactions, and crosstalk with the bone marrow niche. Focusing on these early events underscores the importance of viewing myeloid neoplasia from its cellular and microenvironmental origins.
    Keywords:  Bone marrow niche remodeling; Clonal hematopoiesis; Hematopoietic stem cell dysregulation; Myeloid neoplasia
    DOI:  https://doi.org/10.11406/rinketsu.67.1061
  3. Methods Mol Biol. 2027 ;3093 167-184
      Mitochondrial metabolism plays a central role in regulating muscle stem cell (MuSC) quiescence, activation, and differentiation, with dynamic metabolic transitions accompanying changes in cell fate and function. Flow cytometry-based analysis of mitochondrial function provides a rapid and accessible approach to characterize metabolic states at the single-cell level. Here, we present a detailed protocol to analyze mitochondrial activity, particularly by assessing mitochondrial membrane potential and mitochondrial mass in freshly isolated MuSCs and myoblasts using the fluorescent dyes TMRE and MitoTracker Deep Red in cytometry. This method is compatible with antibody-based identification of MuSCs and includes controls using mitochondrial uncouplers to validate ΔΨm-dependent staining. This protocol enables reliable discrimination between quiescent, activated, and differentiating muscle cells and can be applied to study physiological and pathological conditions in different contexts, including injury, aging, and diseases.
    Keywords:  Flow cytometry; Metabolism; MitoTracker; Mitochondria; Satellite cells; Skeletal muscle; Stem cells; TMRE
    DOI:  https://doi.org/10.1007/978-1-0716-5643-3_13
  4. Pharmacol Res. 2026 Oct 27. pii: S1043-6618(26)01623-3. [Epub ahead of print]234 109708
      Mitochondrial dysfunction drives diseases, including ischemia-reperfusion injury, neurodegenerative disorders, cardiovascular disease, metabolic syndrome, and inflammation. Conventional mitochondria-targeted strategies offer only partial rescue and are insufficient for severe, irreversible damage. Mitochondrial transplantation (MT)-the delivery of exogenously isolated functional mitochondria to injured cells-has emerged as a promising therapeutic strategy that directly restores mitochondrial bioenergetic function and may subsequently modify the tissue microenvironment. This Review examines the entire MT pipeline, from mitochondrial source selection, isolation and preservation, to in vivo delivery strategies. We critically examine the multiple mechanisms underlying MT's therapeutic efficacy, including cellular uptake and intracellular integration, energy restoration and metabolic reprogramming, redox rebalancing, remodeling of mitochondrial quality control (fusion/fission, mitophagy, biogenesis), and immunomodulation. We summarize preclinical and clinical applications across multiple organ systems-heart, nervous system, liver, kidney, lung, skeletal muscle, retina-as well as in oncology and aging. We analyze five major translational bottlenecks: the lack of standardized manufacturing protocols, undefined dose-response relationships, immunogenicity and long-term safety uncertainties, the decisive impact of mitochondrial heterogeneity, and regulatory ambiguity. We outline future directions-mechanistic deepening, engineered target delivery, individualized mitochondrial medicine, combinatorial regimens, and a phased clinical roadmap. MT is not merely energy supplementation; it may reshape cellular metabolism, quality control networks, and immune microenvironments, representing a shift from pharmacological modulation of mitochondrial function toward organelle replacement strategies. Despite challenges, these advances may facilitate individualized mitochondrial therapies as a proposed future direction.
    Keywords:  Clinical translation; Individualized mitochondrial medicine; Metabolic reprogramming; Mitochondrial dysfunction; Mitochondrial quality control; Mitochondrial transplantation
    DOI:  https://doi.org/10.1016/j.phrs.2026.109708